COVID-19

Programme

• 13:30 – 13:40 6 Min. 4 Min.

  • Abstractvortrag (Best Abstract)
  • VS-13-1 (Best Abstract)

  SARS-CoV-2 infects red blood cell progenitors and dysregulates hemoglobin and iron metabolism

  • Dr. Romy Kronstein-Wiedemann (Dresden / DE)

   19. COVID-19, 2. Versorgungsforschung
• 13:40 – 13:50 6 Min. 4 Min.

  • Abstractvortrag
  • VS-13-2

  Increased plasma level of soluble P-selectin in non-hospitalized COVID-19 convalescent donors

  • Dr. Rebecca Müller (Mannheim / DE)
  • Prof. Dr. Peter Bugert (Mannheim / DE)

   10. Hämostaseologie – Koagulopathien, Plasmaderivate und Hämophilie, 19. COVID-19
• 13:50 – 14:00 6 Min. 4 Min.

  • Abstractvortrag
  • VS-13-3

  Long-term Follow up (> 1 year) of Plasma Donors and Patients treated with COVID-19 Convalescent Plasma within the CAPSID trial

  • Dr. med. Sixten Körper (Ulm / DE)

   19. COVID-19, 9. Hämotherapie
• 14:00 – 14:10 6 Min. 4 Min.

  • Abstractvortrag
  • VS-13-4

  A Randomised Open-Label Trial of Early, Very High-Titre Convalescent Plasma Therapy in Clinically Vulnerable Individuals with Mild COVID-19 as model of early treatment in a pandemia with a new pathogen: Experience from collection of very high-titer plasma from superimmunized individuals

  • Dr. med. Sixten Körper (Ulm / DE)

   1. Blutspende und Donormanagement, 19. COVID-19
• 14:10 – 14:20 6 Min. 4 Min.

  • Abstractvortrag
  • VS-13-5

  Humoral and cellular immunity after the third vaccination against SARS-CoV-2 in hematopoietic stem cell transplant recipients

  • Laura Thümmler (Essen / DE)

   11. Hämatopoetische Stammzellen– Grundlagenforschung und Transplantation, 19. COVID-19
• 14:20 – 14:30 6 Min. 4 Min.

  • Abstractvortrag
  • VS-13-6

  COVID-19 causes a change in the dynamics of hemostasis during extracorporeal membrane oxygenation (ECMO)

  • Daniel Rother (Gießen / DE)

   19. COVID-19, 2. Versorgungsforschung